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Abstract: Campylobacteriosis is the most commonly reported gastrointestinal disease in humans.
Campybacter jejuni is the main cause of the infection, and bacterial colonization in broiler chickens is
widespread and difficult to prevent, leading to high risk of occurrence in broiler meat. Phage therapy
represents an alternative strategy to control Campylobacter in poultry. The aim of this work was
to assess the efficacy of two field-isolated bacteriophages against experimental infections with an
anti-microbial resistant (AMR) Campylobacter jejuni strain. A two-step phage application was tested
according to a specific combination between chickens’ rearing time and specific multiplicities of
infections (MOIs), in order to reduce the Campylobacter load in the animals at slaughtering and to limit
the development of phage-resistant mutants. In particular, 75 broilers were divided into three groups
(A, B and C), and phages were administered to animals of groups B and C at day 38 (Φ 16-izsam) and
39 (Φ 7-izsam) at MOI 0.1 (group B) and 1 (group C). All broilers were euthanized at day 40, and
Campylobacter jejuni was enumerated in cecal contents. Reductions in Campylobacter counts were
statistically significant in both group B (1 log10 colony forming units (cfu)/gram (gr)) and group C
(2 log10 cfu/gr), compared to the control group. Our findings provide evidence about the ability of
phage therapy to reduce the Campylobacter load in poultry before slaughtering, also associated with
anti-microbial resistance pattern.
Keywords: anti-microbial resistance (AMR); broiler chickens; Campylobacter jejuni; phage therapy
1. Introduction
Campylobacter is the most commonly reported gastrointestinal bacterial pathogen in
humans in the European Union (EU) since 2005, with 220,682 confirmed cases of Campy-
lobacteriosis in 2019 [1]. Campylobacter spp., in particular Campylobacter jejuni (C. jejuni) and
Campylobacter coli (C. coli), are ubiquitous in nature, and their niche seems to be the intesti-
nal mucosa of warm-blooded hosts [2,3], especially those of avian species. In poultry, the
natural bacterial colonization is mainly associated with horizontal transmission at the farm
level, and to a lesser extent to vertical transmission [4], with a mean prevalence in the EU
of 71.2% of broiler batches [5]. While Campylobacter in chickens does not cause any visible
symptoms, in humans some strains can lead to severe disease, with clinical signs like fever,
headache, abdominal pain and diarrhea, nausea, and vomiting. Most cases of Campylobac-
teriosis are self-limiting, but there is the potential of post-infection complications such as
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Guillain-Barre syndrome, irritable bowel syndrome, and septicemia [6]. Animal-to-human
transmission is mostly related to the food route: the consumption of undercooked poultry
meat and the cross-contamination from other foods during the preparation of poultry
meat are significant risk factors [7]. However, human infections are also caused by Campy-
lobacter isolates originating from cattle or other animals [8–10], while person-to-person
transmission is considered relatively uncommon [11].
Nowadays, the increasing problem of multi-drug resistance to antibiotics largely used
in animals and humans, and in particular to treat C. jejuni infections, is considered a serious
threat to public health [12]. Both the global burden related to anti-microbial resistance
(AMR) [13] and the increasing trends of hospitalizations for many zoonotic bacteria such as
Campylobacter spp. [14] have clear public health and economic implications. In this scenario,
it is well known that the farm level plays a key role regarding the entrance of Campylobacter
into the food chain, thus leading to the risk for consumers to be infected, especially via
poultry meat consumption [15]. The EU summary report on AMR in zoonotic and indicator
bacteria from humans, animals, and foods underlines the worrying levels of resistance
to ciprofloxacin, nalidixic acid, and tetracycline [13]. According to an opinion from the
European Food Safety Authority (EFSA) [16], the reduction of Campylobacter counts by
more than 2 log10 units in meat could reduce the public health risk for human consumers
to contract Campylobacteriosis after the consumption of chicken meals by more than 90%.
For these reasons, studies are necessary to find more alternatives and safe measures
to reduce Campylobacter spp. loads in chickens. Intervention strategies such as feed and
water additives, vaccines, and biosecurity measures have been deeply investigated [17].
Recently, researchers have returned to bacteriophages as promising and welfare-friendly
tools for the biological control of Campylobacter spp. on farms [16]. Among the innovative
strategies also suggested by EFSA experts, bacteriophage-based applications in chickens
could play an important role in reducing the load of Campylobacter spp. in the birds [16].
Bacteriophages (or phages) are the most abundant biological entities on earth [18,19], and
their efficacy to reduce Campylobacter spp. in broiler chicken ceca [20] and on the surface of
chicken skin [21] has already been demonstrated. The data of a recent study showed that
exposure of the rat gut microbiome to a cocktail of commercial phage preparations active
against Salmonella enterica, Staphylococcus aureus, Streptococcus pyogenes, Proteus (P.) mirabilis,
P. vulgaris, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli resulted in
dysbiosis with increased inflammation and gut permeability [22]. However, Campylobacter
bacteriophage applications in poultry demonstrated the ability to reduce C. jejuni counts
without affecting the microbiota structure of the animals [23]. The key to a meaningful
intervention within flocks is based on a mix of factors that range from the selection of
efficient phages and the use of specific multiplicities of infection (MOIs) to methods and
timing of phage-based applications in poultry [24].
Moreover, another problem encountered in phage therapy is related to the develop-
ment of phage-resistant bacterial mutants [25] that could render any phage-based applica-
tions unsuccessful. In order to avoid this problem, many authors, instead of using only one
phage in their in vivo trials [20,26], suggested the use of phage cocktails [23,27] instead.
The aim of this research was to assess the in vivo efficacy of two field bacteriophages
to reduce the load of an experimental AMR Campylobacter jejuni strain in broilers before
slaughtering. To achieve meaningful results in terms of Campylobacter spp. reduction, the
authors worked especially on two specific aspects: the timing of phage administration
in chickens and the MOIs to apply. In particular, in our study a different and innova-
tive approach not used before, based on a sequential application of two different phages
(specifically isolated from poultry farms) administrated individually after a 24-h interval,
one day before slaughtering, was adopted in order to limit any potential occurrence of
phage-resistant Campylobacter strains [25]. Moreover, because of the worldwide growing
concern about AMR, a specific Campylobacter strain (252 gM/12A) was used in this study,
chosen on the basis of its anti-microbial resistance pattern against some antibiotics fre-
quently used in veterinary and human medicine (ciprofloxacin and nalidixic acid) [28].
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The preliminary results reported in this paper are extremely encouraging; in fact, the
reduction of Campylobacter loads in broilers of 2 log10 units would reduce the public health
risk for the human consumers to get Campylobacteriosis by eating contaminated chicken
meals by up to 90% [16]. Moreover, the two field bacteriophages administered to poultry
before slaughtering showed activity against a specific AMR Campylobacter strain, and this
was another important finding that deserves more in-depth investigations, also with the
support of specific field studies to be carried out in the near future.
2. Materials and Methods
2.1. Campylobacter Strains and Bacteriophages
The bacterial strain used for chicken infection in the trial (C. jejuni 252 gM/12A) was
isolated from poultry farms and characterized within the Italian Reference Laboratory for
Campylobacter. This specific strain was chosen among the others because of its particular
sensitivity to bacteriophages and for its AMR pattern against ciprofloxacin and nalidixic
acid, antibiotics frequently used in veterinary and human medicine [28]. The strain was
sub-cultured from the original frozen cryogenic bead stocks and incubated under micro-
aerobic conditions (85% nitrogen, 5% oxygen, and 10% carbon dioxide) at 42 ◦C for 48 h
(h), according to the International Standard Organization (ISO) method 10272–1 (2006).
To achieve the concentrations suitable for the trial (105 colony-forming unit (cfu)/milliliter
(mL)), bacterial cell suspensions were diluted in 10 mL of phosphate-buffered saline (PBS;
Dulbecco’s Formula Modified, ICN Biochemicals, Thame, Oxfordshire, UK).
The bacteriophages used in this study, Φ7-izsam and Φ16-izsam, were previously
isolated and morphologically characterized, as reported by Aprea et al. (2018) [29]. In par-
ticular, these phages were ascribed to the Caudovirales order, Myoviridae family, Group
A, thus belonging to double-stranded DNA viruses [29], and were chosen for their wide
host-range spectrum and their particular activity against AMR C. jejuni strains [28]. Before
the experiment, the two bacteriophages were subjected to a three-step plaque purification
assay, in order to assure their purity. Briefly, for each purification step, the plaques were
individually picked up from the agar and eluted into 2 mL of SM buffer (0.05 M TRIS, 0.1 M
NaCl, 0.008 M MgSO4, 0.01% (weight in volume) gelatin, pH 7.5) for 8–9 h at room temper-
ature; then the supernatant was filtered with 0.45 micrometer (µm) filters. Subsequently,
1 mL of Campylobacter broth culture (252 gM/12A field strain) was added to 1 mL of the
supernatant and left for 15 min at 37 ± 1 ◦C in aerophilic conditions, to allow phages to
adsorb on the bacterial cells. At the end of the incubation period, the culture was added to
4 mL of New Zealand Casamino Yeast Medium (NZCYM) soft agar (NZCYM broth + 7
grams (g)/liter (L) of agar - Life Technologies, Milan, Italy), poured on a plate of NZCYM
agar (NZCYM broth + 15 g/L agar - Life Technologies, Milan, Italy), and incubated at
37 ± 1 ◦C in micro-aerophilic conditions for 48 h. After the incubation, the plate was
coated with 5 mL of SM buffer. The soft agar was gently fragmented with a sterile loop
and left to elute for 6 h at room temperature under gentle agitation (60 run per minute
(rpm)). The supernatant was then filtered with 0.45 µm filters and subjected to titration.
This procedure was repeated three times. The two bacteriophages were finally subjected
to further replication steps for increasing their titers, individually [17]. To reach the final
concentration loads (107 plaque-forming unit (pfu)/mL for MOI 0.1 and 108 pfu/mL for
MOI 1) for the in vivo trial, phage suspensions were prepared via dilutions in SM broth,
with the addition of 30% w/v of calcium carbonate (CaCO3), to prevent phage inactivation
by the acidity of the chickens’ stomachs.
2.2. Broiler Rearing and In Vivo Trial
For the in vivo trial, the Ross 308 broiler chickens were chosen. The number of
animals was reduced to the minimum required to ensure statistically positive results: in
total, 75 chickens were enrolled in the assay. The animals were housed in an environment
with enrichments in order to stimulate motor activity for their welfare. In the shelter room,
infrared lamps were used to provide the optimal temperature for the animals (Table 1).
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Table 1. Optimal temperatures at which the animals were housed at different days of life during the
in vivo trial.














The animals were placed on a soft surface to ensure the manifestation of strictly specific
behaviors such as fluttering wings and distortion of the paws. The relative humidity (RU)
was adjusted according to the age of the animals. In particular, from day 1 to day 4 of life,
RU was maintained at 65/70%, and from day 5 to day 37 of life, at 60%. The animals were
exposed to 24 h of light for the 1st week of life, following a natural day/night cycle from
the 2nd week of life to the end of the experiment. The animals were reared in a single group
from day 1 to day 36, at the feeding conditions described in Table 2. Both environmental
temperatures (Table 1) and feed formulations (Table 2) were adapted from the standard
rearing conditions.
Table 2. Animal feeding conditions during the in vivo trial.
Days of Life Feed
0–10 days Starter feed
11–21 days 1st growing feed
22–30 days 2nd growing feed
31–39 days Finishing feed
The experimental phases of the in vivo trial are summarized in Table 3.
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In particular, at day 0, soon before the experimental infection, cloacal swabs from
birds were assessed in order to check the birds for the absence of natural Campylobacter spp.
infections (ISO 10272: 2006 Part 1). For 1-day chicks, C. jejuni 252 gM/12A (0.1 mL of the
bacterial suspension 105 cfu/mL) was administered via oral gavage using a sterile 5 mL
volume syringe and a detachable 6 cm-long cannula. At day 10, cloacal swabs were taken
using swabs (Medical Wire & Equipment: MW171) and the Campylobacter colonization was
verified, using standard accredited methods (ISO 10272: 2006 Part 1 and Part 2). At day 30, a
statistically significant number of birds (n = 6) were sacrificed, and the Campylobacter count
in their gut content was assessed and recorded in order to set up the phage suspensions at
MOI 0.1 and 1. At day 37, the animals that survived were randomly subdivided into three
experimental groups (A, B, and C) of 23 animals each. The day after (day 38), birds of group
A, representing the negative control, were treated with SM broth with the addition of 30%
(w/v) CaCO3 (SM-CaCO3). Bacteriophages were administered to chickens in groups B and
C via oral gavage in the following conditions: experimental group B chicks were orally
treated with φ16-izsam at MOI 0.1 (phage suspension of 107 pfu/mL); and experimental
group C chicks were treated with Φ16-izsam at MOI 1 (phage suspension of 108 pfu/mL).
The next day (day 39), the other phage, Φ7-izsam, was administered at MOI 0.1 to animals
of group B and at MOI 1 to animals of group C. The animals of group A received SM-CaCO3
only. At day 40, all the birds from the three groups were sacrificed and C. jejuni loads were
assessed from cecal contents (ISO 10272: 2006 Part 1 and Part 2). In particular, 40 days
of life is the age at which animals are industrially slaughtered to reach a commercial
weight of about 2.8 kg. The results among the experimental groups were statistically
analyzed to verify significant differences within the infection levels. In particular, the
non-parametric Mann–Whitney test was applied for independent samples. For statistical
analysis, the XlStat ver. 2013.2.04—Addinsoft software was used.
3. Results and Discussion
The physical response of chickens administered with the C. jejuni field strain and/or
bacteriophages was indistinguishable from that of the control birds in terms of no apparent
loss of appetite, no reduction in weight gain, no alteration in locomotion, and no diarrhea
or respiratory distress. Post-mortem examination of major organs (i.e. hearts, livers,
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and kidneys) did not show any macroscopically appreciable pathological abnormalities
in all treated birds. At this stage, the authors did not assess any potential dysbiosis side
effects nor the presence of markers for inflammation in the phage-treated animals. Due
to the experimental design and the results of the post-mortem analysis, and as supported
by the results of previous works [23], it is likely that no adverse effects were potentially
present in this study. However, more in-depth analyses will be carried out in future
scale-up trials in relation to these specific features. Data on whole-genome sequences
from Φ7-izsam and Φ16-izsam could not be reported at the present because this material
is still undergoing a patent registration process. However, these two phages satisfied
all the preliminary criteria for safety evaluation; i.e. absence of genes coding for AMR,
integrases, or toxic factors. The overall results from the in vivo trial are reported in Table
3. In particular, at day 0, no Campylobacter was found in the swab samples. At day 10, C.
jejuni had an average infection load of 108 cfu/mL, demonstrating an effective bacterial
colonization in the animals under assessment. At day 30, a partial slaughtering of chickens
was necessary for the evaluation of the average C. jejuni infection load for the preparation
of the experimental phage suspensions to be administered to experimental groups (MOI
0.1 and 1). At this time, the C. jejuni colony numbers recovered from the cecal contents
were 108 cfu/gr. At day 40, the C. jejuni count showed a significant difference between
bacteriophage-treated birds (B and C) and control birds (A) throughout the experimental
period investigated. In particular, in the lower intestine of birds from control group A, the
C. jejuni load was 108 cfu/gr, while both treated groups showed the following infection
levels: 107 cfu/gr for group B treated with phages at MOI 0.1; and 106 cfu/gr for group
C treated with phages at MOI 1. These results showed a total reduction in Campylobacter
numbers of 1 log10 for group B and of 2 log10 for group C (Table 3). The non-parametric
Mann–Whitney test applied for independent samples revealed that the differences among
the C. jejuni infection loads from the three experimental groups were statistically significant
(p < 0.0001).
The bacteriophages assessed in this study were previously isolated by applying a
novel protocol based on the use of a broader spectrum of bacteria—a mix of Campylobacter
strains with somatic and flagella antigenic differences—in order to amplify the chance
to detect, in the poultry environment, a more diversified group of lytic phages against
C. jejuni [29]. Bacteriophages (Φ7-izsam and Φ16-izsam) were chosen for the in vivo trial
because of their wide host-range spectrum and for particular virulence activity against
AMR C. jejuni strains [28]. In particular, these phages showed in vitro lytic activities against
C. jejuni strains resistant to cyprofloxacin, nalidixic acid, and tetracycline. It is worth noting
that the authors previously reported a very interesting and important finding: the loss of
resistance to antibiotics in C. jejuni strains, verified with the change of the antimicrobial
resistance spectrum assessed by antibiotic-susceptibility tests [28]. This feature has been
rarely exploited by scientists, and the first evidence was reported by EFSA experts in
2016 [30]; in particular, Listeria monocytogenes strains originally resistant to ciprofloxacin and
erythromycin were shown to revert to being antibiotic-sensitive after infection with ΦP100.
The authors believe that the timing of phage administration in poultry is also a deter-
minant factor for success in phage applications, because of the high risk of development
of phage-resistant bacterial mutants. In this regard, Wagenaar et al. (2005) [26] demon-
strated that after the initial 3 log10 reduction of C. jejuni counts after phage applications,
the Campylobacter load increased again within five days and plateaued at 1 log10 lower than
the controls. To avoid this problem and to reduce the time for resistant strains to emerge,
Carvalho et al. (2010) [27] proposed a cocktail of phages rather than just one phage, and
achieved an approximately 2 log10 reduction. Loc Carrillo et al. (2005) [25] demonstrated
that increasing the time between treatment and slaughter from 24 h to 2–4 days may reduce
the effective decrease of Campylobacter spp. counts in the cecal contents of phage-treated
broiler chickens. In particular, they demonstrated values of Campylobacter reduction levels
from 0.5 log10 to 5 log10 after phage applications in in vivo trials. Kittler et al. (2013) [31]
instead reported very variable results, according to the type of phage used (from no evident
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C. jejuni reduction to 3.2 log10 cfu/gr lower bacterial counts than in the control). In the
present study, to minimize the potential development of Campylobacter mutants resistant
to phages, the authors administered, for the first time in science, two different bacterio-
phages, Φ16-izsam and Φ7-izsam, 24 h apart from each other, with the second applied
24 h before slaughtering. Chickens were treated with two different phage MOIs (0.1 and
1), chosen on the bases of the results of previous in vitro efficacy tests [32]. In particular,
in our preliminary in vitro results, we already experienced the possible success of this
sequential administration of two different phages; in fact, Campylobacter’s growth trend not
only was maintained at lower levels after the second phage application when compared
to the negative (non phage-treated) control, but also in the Campylobacter cultures treated
with only one phage (Φ16-izsam).
The experimental trial within this research demonstrated that both the MOIs used
produced an efficient reduction in C. jejuni counts in the chicken guts one day after ad-
ministration of the second phage suspension. These results suggest the possibility that
bacteriophages may be administered shortly before slaughter (phage administrations
completed 24 h before slaughtering), subsequently minimizing the risk to disseminate
potential phage-resistant Campylobacter strains in the farm environment. In the present
study, the authors did not assess the development of phage-resistant mutants but this issue
will be analyzed more in-depth in future scale up trials. Our results are in line with those
reported by the authors previously cited. In particular, we achieved a total reduction in
C. jejuni numbers of 1 log10 for those birds treated with MOI 0.1, and 2 log10 for those
treated with MOI 1. Nevertheless, opinions diverge regarding which MOI could be the
best to apply to obtain the most efficacious results. Tomat et al. (2013) [33] suggested that
the application of higher numbers of phages and higher MOI values (>1) will result in a
greater reduction of the numbers of the pathogen (passive-mode applications [34]). In the
authors’ laboratory experience, the use of low MOIs (≤1) has always been more successful
when compared to the use of higher MOIs (>1), both in vitro [32] and in vivo (present
study). This evidence supports the “active mode of phage-therapy” as stated by Cairns
et al. (2009) [34]: “The phage concentration will not exhibit net growth unless the host
concentration is above the appropriate proliferation threshold, and when this occurs phage
proliferation becomes relatively rapid until the phage concentration reaches the inundation
threshold and begins to suppress the host population”.
The results achieved in this study are very encouraging; in fact, according to the EFSA
opinion adopted in 2011 [16], the reduction of Campylobacter contamination loads in broiler
meat of 1–2 log units would reduce the public health risk for human consumers to contract
Campylobacteriosis associated with consumption of chicken meals by up to 90%.
In commerce, no phage-based applications against Campylobacter spp. are available
at the moment. Nevertheless, since the veterinary use of antibiotics is very controversial
because of AMR, phage therapy may become more generally accepted. Our results clearly
show that phage therapy is able to control infections in broilers also caused by AMR C.
jejuni strains. Moreover, as expected [23], the phage administration in chickens showed no
detectable adverse effects; e.g. abnormal physical response, loss of appetite, reduction in
weight gain, alteration in locomotion, or diarrhea or respiratory distress.
More research and scale-up trials are needed to improve the efficiency of phage ther-
apy, to explore the robustness of this experimental approach when applied to modern
chicken-management systems, and to assess the phage efficacy versus different Campylobac-
ter field populations in natural breeding conditions. Phages are generally given to animals
in feed or water [27] as simple purified viral suspensions or after microencapsulation [35].
In particular, the most effective and suitable method for Φ7-izsam and Φ16-izsam adminis-
tration in poultry on an industrial scale needs to be explored in more details in the near
future. Very recently, some authors have speculated about the cost benefits related to the
use of phages in therapy [36]. Though the opinions are very different, in general, high-scale
phage productions are of relatively low cost when compared to the production of new
classes of antibiotics. Moreover, the efficacy of phage-based formulations has been exten-
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sively demonstrated, including few side effects when compared to the large burden related
to AMR when over-using some classes of chemicals [13]. This may also illuminate aspects
such as the evaluation of the carriage and shedding of Campylobacter spp. from infected
birds, together with comparisons about the release of C. jejuni in the slaughter process,
both from phage-treated animals and from naturally infected and non-treated birds.
4. Conclusions
Campylobacter colonization in poultry poses a serious threat to human health when
entering the food chain after slaughtering. The field bacteriophages tested in this research
in an in vivo assay were able to assure efficacy by reducing the total load of bacterial
contamination by up to 2 log10 in experimentally infected birds. In particular, the results
were obtained against a specific AMR Campylobacter jejuni strain. An innovative two-step
phage administration, 24 h before slaughtering, was applied with the use of low phage
MOIs (0.1 and 1).
The effective treatment achieved in this research demonstrated that the alternative
phage-therapy approach proposed in this in vivo trial to contrast Campylobacter in poultry
should be deeper investigated in scaled-up field trials, and deserves serious attention for a
potential application in the future.
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